Premium
Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus
Author(s) -
Bäckman L.,
Varberg Reisæter A.,
Wramner L.,
Ericzon B.G.,
Salmela K.,
Brattström C.
Publication year - 2006
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2006.00489.x
Subject(s) - medicine , calcineurin , sirolimus , urology , renal function , renal transplant , immunosuppression , creatinine , kidney , transplantation , liver transplantation , gastroenterology
Two Six‐month pilot studies were conducted in renal (n=17) or liver (n=15) transplant recipients to evaluate renal function after conversion from calcineurin inhibitor (CI)‐ to sirolimus (SRL)‐based immunosuppression. After an SRL loading dose, doses were individualized to achieve whole blood trough levels of 10–22 ng/mL. Overall, serum creatinine did not change from baseline to six months post‐conversion but an improvement from 219.9 to 201.4 μmol/L at three months was noted in renal transplant recipients (p<0.05). Another finding was a numerical increase in the mean glomerular filtration rate (GFR) from 26.8 to 33.2 mL/min/1.73 m 2 at six months among liver transplant recipients (NS). All patients survived and all grafts were functioning at the end of the study. In conclusion, renal function remained stable, with a tendency towards improvement, after abrupt conversion from CI‐ to SRL‐based therapy in renal or liver transplant recipients with moderate renal insufficiency.